Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) recently received a drug registration approval letter for its sevelamer carbonate from the US Food and Drug Administration, a Monday Hong Kong bourse filing said.
The marketing of sevelamer carbonate (active pharmaceutical ingredients) has been approved following the completion of a review of the relevant drug master file.
Sevelamer carbonate is used to control hyperphosphatemia in adult patients with chronic kidney disease who are undergoing dialysis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments